Publications by the researcher in collaboration with M. Iborra Colomino (19)

2024

  1. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

  2. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5

2023

  1. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  2. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  3. Splanchnic Vein Thrombosis in Inflammatory Bowel Disease: An Observational Study from the ENEIDA Registry and Systematic Review

    Journal of Clinical Medicine, Vol. 12, Núm. 23

2022

  1. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

    Biomedicines, Vol. 10, Núm. 3

  2. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  3. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry

    Digestive and Liver Disease, Vol. 54, Núm. 5, pp. 635-641

  4. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

2021

  1. Effectiveness and safety of methotrexate monotherapy in patients with Crohn’s disease refractory to anti-TNF-α: results from the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 53, Núm. 9, pp. 1021-1029

2020

  1. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596

2019

  1. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

  2. Effectiveness and safety of the switch from remicade® to CT-P13 in patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 13, Núm. 11, pp. 1380-1386

  3. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

    Therapeutic Advances in Gastroenterology, Vol. 12

  4. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 3, pp. 278-288

2017

  1. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients

    Journal of Gastroenterology, Vol. 52, Núm. 7, pp. 788-799

  2. Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients (J Gastroenterol, 10.1007/s00535-016-1274-1)

    Journal of Gastroenterology

  3. Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry

    American Journal of Gastroenterology, Vol. 112, Núm. 7, pp. 1135-1143

2016

  1. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab

    Biochemical Pharmacology, Vol. 122, pp. 33-41